Onkológia 3/2024

Optimal treatment sequence in the treatment of locally advanced unresectable and metastatic urothelial carcinoma under current reimbursement mechanisms in Slovakia

This review article discusses treatment options for locally advanced unresectable and metastatic urothelial carcinoma in the current era of immunotherapy and antibody-drug conjugates. It presents current data from the ongoing multicenter ambispective French study AVENANCE, which also includes patients with worse performance status, older age, pretreated with carboplatin and gemcitabin, with a higher load of visceral metastases, and therefore better reflects the treatment and results in the usual clinical practice of an oncologist. With an optimal treatment sequence and response to treatment, it is possible to achieve a median of overall survival more than 3 years. The work also touches on a new standard in the first line of treatment. At the end of the article, We present a case report of a patient, who achieved complete metabolic remission of the disease.

Keywords: urothelial carcinoma, chemotherapy, maintenance therapy, immunotherapy, antibody-drug conjugates